Last mentioned: Mar 19, 2026
Insider Sale
CMO Rui Avelar sells 29,996 shares of EOLS stock.
Revenue Targets Raised
Management increases 2028 revenue goals citing market stabilization.
SEC Filing Update
Company files notice regarding changes or departures in director/officer roles.
Earnings Release
Company reports Q4 beat and issues bullish 2026 revenue guidance.
Q4 Earnings Beat
Evolus reports record results and triggers a significant stock rally.
Evolysse Launch
Anticipated commercial rollout of the Evolysse dermal filler portfolio in the U.S.
Q4 Fiscal Close
Evolus concludes its strongest fiscal year to date with record Jeuveau sales.
Evolus Chief Medical Officer Rui Avelar sold 29,996 shares of EOLS stock on March 19, 2026, following a period of significant price appreciation. The transaction occurs as the aesthetics company raises its long-term revenue targets and reports stabilizing trends in the neurotoxin market.
Evolus reported record Q4 2025 financial results, triggering a significant stock rally following a revenue beat and robust 2026 guidance. The company's performance underscores the resilience of the medical aesthetics market and the growing adoption of its flagship neurotoxin, Jeuveau.